Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Less propofol during brain surgery may lead to quicker, safer awakening

NCT ID NCT06844838

First seen Feb 18, 2026 · Last updated Jun 23, 2026 · Updated 17 times

Summary

This study is testing whether using lower doses of the anesthetic drug propofol during brain tumor surgery helps patients wake up more quickly and fully after the operation. Researchers will enroll 100 adults having elective brain surgery and monitor their recovery. The goal is to find the best balance between keeping patients asleep during surgery and ensuring a smooth, early awakening afterward.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SUPRATENTORIAL BRAIN TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    RECRUITING

    Milan, 20133, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

propofol and remifentanil (anesthetic drugs)

What this could lead to

If it works, this could lead to a standard way to give anesthesia that helps brain surgery patients wake up sooner and more clearly.

What could go wrong

This is a small, early-phase study (100 people) at one hospital. The results may not apply to all patients, and the approach might not improve outcomes or could have unknown risks.

Conditions

The condition(s) this trial relates to.

Pain supratentorial cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.